EMA review puts Avastin's EU breast cancer indication at risk
This article was originally published in Scrip
Executive Summary
The EMA has begun an unexpected review of the benefits and risks of Roche's Avastin (bevacizumab) to treat first-line metastatic breast cancer - an indication for which the drug has full approval in the EU (in combination with paclitaxel and docetaxel chemotherapy).